

3rd Annual Meeting

World CTC

USA

12th - 15th November 2012, Boston

Unleashing the commercial potential of CTCs & demonstrating practical applications in the clinic

"The World CTC Summit is an excellent opportunity to get up to date on current standards and even more for networking in the field!"

Bayer

15+hrs
of Networking

World's
Largest CTC
Meeting

200+
CTC Experts

50+
Speakers

2 Streams
Industry Stream &
Science Stream

Sponsors





World CTC Contents

What will you learn?

Benefits of attending	page 3
Agenda at a glance	page 6
Agenda in full	pages 10-15
Interactive workshops	pages 16-17
World CTC at a glance	page 18

Who will you meet?

Who should attend	page 7
Networking at World CTC	page 8
Bring your team	page 9
Academic and clinician attendees at World CTC	page 21

Book your place

Venue & accommodation	page 26
Registration & pricing	page 27

Who will you hear from?

Speakers at a glance	pages 4-5
Speakers in full	pages 22-25

Sponsorship

Sponsorship opportunities	page 19
Sponsors	page 20

LinkedIn

Start discussions early and connect with your peers.
Search groups for “**Circulating Tumor Cells Forum**”

twitter

Get weekly updates on CTC news through twitter.
Follow us here: **@World_CTC**



Benefits of Attending

Harness the Potential of CTCs in the Clinic

Advances in CTC technologies are facilitating dramatically improved patient diagnosis and treatment decisions. The implications for drug development and patient care are profound.

Do you understand exactly how your organization can benefit?

With CTCs finally moving from bench to bedside, World CTC is bringing together the leading clinical minds alongside pioneering drug developers and academics to discuss progress in this field. Join us at World CTC to learn how you can use CTC technology to optimize drug development and clinical management of your patients.

Benefits of attending World CTC:

- 1 Get first-hand clinical data to discover how leading clinicians are utilizing CTCs to **improve patient management decisions** at **Massachusetts General Hospital, Fox Chase Cancer Centre** and **MD Anderson**
- 2 Understand how you can better **predict clinical response of your patients using new knowledge of tumor cell biology** derived from molecular characterization of CTCs
- 3 Evaluate **the most promising new CTC technology platforms**, understand their utility in the clinic, and know which ones to adopt within **your** company
- 4 Hear for the **first time success stories from drug developers using CTC technologies** in clinical trials to identify the right drug for the right patient with **Johnson and Johnson, Genentech** and **Pfizer**
- 5 Promote your business, research or CTC technology by making connections in our **speed networking, 1-2-1 meetings and poster session** to forge new relationships within the **biggest network of CTC experts all under one roof**
- 6 Take away practical solutions to your specific challenges with information from our **in depth workshops**. Learn the importance of **tumor molecular profiling in healthcare delivery and drug development** and find out how to **negotiate the regulatory pathway to commercialization**
- 7 Learn **how to use CTCs as an accurate predictor of clinical outcome** with **results from many real world clinical studies** showing statistically significant correlations between cancer patients and CTCs
- 8 **Develop a comprehensive strategy for integration of CTCs** into your drug development as an accurate predictor of treatment response and clinical outcome, by hearing how **EMD Serono** and **Progenics** are achieving this
- 9 Understand **the economics behind personalized medicine**, determine the cost effectiveness of CTCs as a biomarker, and get **payer's perspectives on achieving a positive reimbursement decision**
- 10 Successfully **translate your research grade assay into a clinically useful CTC diagnostic test** and achieve assay validation



Speakers at a Glance:

Leading Clinicians



Daniel Boffa

Assistant Professor, Section
of Thoracic Surgery



Yale School of Medicine



Massimo Cristofanilli

Professor of
Medicine



Luis Diaz

Associate Professor of Oncology,
Director of Translational Medicine



Martin Fleisher

Chief, Clinical Chemistry Service,
Department of Laboratory Medicine



Memorial Sloan-Kettering
Cancer Center
The Best Cancer Care. Anywhere.



Oscar Goodman

Medical Director,
Clinical Trials Office



Daniel Haber

Director



Stefanie Jeffrey

Chief of Surgical Oncology
Research



STANFORD
SCHOOL OF MEDICINE



Gavin Robertson

Director



Howard Scher

Chief, Genitourinary Oncology
Service



Shannon Stott

Assistant Professor,
Department of Medicine



MASSACHUSETTS
GENERAL HOSPITAL
CANCER CENTER

Pioneering Drug Developers and Technology Providers



Cynthia Bamdad

Chief Scientific Officer



Yvon Cayre

Chief Scientific Officer



Chris Chiu

Senior Research Investigator



Mark Connelly

Scientific Director, Cellular
Research, Janssen Oncology
Biomarkers & Site Director



Nicholas Dracopoli

Vice President, Biomarkers



Yves Dubaquié

Director, Business Development
& Licensing



Andrea Fan

Associate Director of Biology



Edith Szafer Glusman

Senior Research Associate,
Development Sciences



Ann Kapoun

Vice President, Translational
Medicine



Nicolo Manaresi

Chief Technology Officer



Shannon McGrath

Biomarker and
Personalized
Medicine



Vijay Modur

Head of Diagnostic Discovery




Stanislaw Mikulski

Senior Medical Director



Jaclyn Neely

Senior Research Investigator



David Nelson

President and Chief Scientific
Officer



Bill Olson

Senior Vice President, R&D



Steven Pirie-Shepherd

Associate Director



Denis Smirnov

Associate
Scientific Director,
Oncology
Biomarkers





Speakers at a Glance:

Leading Academics



Alison Allan
Oncology Scientist
and Assistant
Director



Jeffrey Chalmers
Professor, Department
of Chemical and
Biomolecular
Engineering



Richard Cote
Professor and Chair, Department
of Pathology; Director
MIAMI UNIVERSITY
OXFORD, OHIO



Samir Hanash
Program Head, Molecular
Diagnostics
**FRED HUTCHINSON
CANCER RESEARCH CENTER**




Gilbert Faure
Professor of Medicine
**UNIVERSITÉ
DE LORRAINE**



Robert Kinders
Laboratory of Human
Toxicology and
Pharmacology, Applied/
Developmental,
Research Directorate,
SAIC-Frederick
**NATIONAL
CANCER
INSTITUTE**



Michael King
Associate Professor,
Department
of Biomedical
Engineering



Brian Kirby
Associate Professor
of Mechanical
Engineering



Peter Kuhn
Associate Professor, Cell Biology
THE SCRIPPS RESEARCH INSTITUTE



Jerry Lee
Deputy Director,
Office of the Director,
Center for Strategic
Scientific Initiatives



Sabine Mai
Senior Investigator, Manitoba
Institute of Cell Biology, Professor
Manitoba Institute of Cell Biology



Marek Malecki
Associate Professor,
Director
Western University
The art of learning.



Sendurai Mani
Assistant
Professor,
Molecular
Pathology



Dario Marchetti
Professor, Departments
of Pathology &
Immunology and
Molecular & Cellular
Biology



James Reuben
Professor
**THE UNIVERSITY OF TEXAS
MD ANDERSON
CANCER CENTER**
Making Cancer History®



John Viator
Associate
Professor,
Biological
Engineering



Guiren Wang
Assistant Professor,
Department of
Mechanical Engineering
& Biomedical
Engineering Program



Lihua Wang
Senior Scientist,
Applied
Developmental
Directorate
**NATIONAL
CANCER
INSTITUTE**



Robert Zeilinger
Professor



John Zhang
Associate Professor,
Department
of Biomedical
Engineering



Regulation and Reimbursement Specialists



Naomi Aronson
Executive Director,
Technology Evaluation
Center (TEC)



John Bloom
President & Special
Government Employee
Bloom Consulting Services LLC



Patricia Deverka
Senior Research Director
CMTP
Center for Medicare Technology Policy

Evening Drinks Speaker



Michael Stocum
President & CEO



Why attend World CTC?

"A nice balance of vendors, clinicians and researchers in well established, as well as emerging companies. Very useful for key contacts."

Biofluidica Microtechnologies



Agenda at a Glance

■ Plenary Sessions

■ Networking Sessions

■ Commercial Stream

■ Science Stream

■ Workshops

Pre-Conference Activities - 12th November		Main Conference Day 1 - 13th November	Main Conference Day 2 - 14th November	Main Conference Day 3 - 15th November
Workshop A1: Microfluidic Device Design and Analysis for Capture of Circulating Tumor Cells	Workshop A2: Emerging Molecular Biomarkers - Blood-Based Strategies to Detect and Monitor Cancer	Registration & Networking	Registration & Networking	Registration & Networking
		Plenary Session: Circulating Tumor Cells: Capture, Enumeration and Characterization	Plenary Session: Furthering the Use of CTCs in Clinical Trials and Patient Management	Plenary Session: Understanding the Regulatory Requirements for CTCs in Personalized Medicine
Workshop B: Fluid Biopsy of Solid Tumors: Its Many Uses In Clinical Research And Therapy Management		Speed Networking	Morning Networking	Morning Networking
		Industry Stream: CTCs as a Tool to Aid Drug Development	Science Stream: Increasing our Understanding of Cancer Biology Using CTCs	Plenary Session: Advancing Technology in the CTC Field: Increasing Sensitivity and Specificity
Workshop C: Progress in the Development, Application and Commercialization of CTC Capture and Analytical Platforms for Use in Drug and Diagnostics Development Today		Afternoon Networking	Afternoon Networking	Afternoon Networking
		Plenary Session: Advancing Molecular Analysis of CTCs	Plenary Session: Future Approaches to Exploit the Potential Use of CTCs in the Clinic	Plenary Session: Advancing Technology in the CTC Field: Increasing Sensitivity and Specificity
Free Networking Time		Drinks Reception & Networking	Poster Session & 1-to-1 Networking	Close of Conference



Who Should Attend:

World CTC brings together every key stakeholder into one room from across the Circulating Tumor Cell field, to discuss and debate cutting edge technologies, clinical applications, and advance CTC use in drug development.

Lasting 3 days, with over 50 speakers and 200 attendees – this is where all the leading players congregate. If you see the huge potential of CTCs, then join us onsite and become part of the world's largest CTC meeting.



Drug Developers: This meeting will allow you to develop a comprehensive strategy for integrating CTCs into your drug development program and allow you to stratify patients in clinical trials to select the right drug for the right patient. World CTC will show you how your peers such as, **Johnson and Johnson, GSK, Abbott, Pfizer, Genentech, BMS and Novartis**, are overcoming the same challenges you are facing. World leading technology providers will be in the same room to provide solutions.



Payer/Healthcare Providers: The issue of reimbursement is one of the hottest in the commercialization of CTC technology. World CTC provides the opportunity to meet key contacts from drug and diagnostic companies, and get your most pressing questions addressed, including future reimbursement plans, incentives and patient care.



Academics: Get the latest updates from leading research institutes on how CTCs are increasing our understanding of the biology of cancer thanks to advancing molecular characterization and analysis techniques. And discover the latest advances in our understanding of the role of CTCs in metastatic disease.



Clinicians: This meeting gives you an unrivalled opportunity to hear expert case studies from the leading cancer institutes across the USA. To help you drive forward routine clinical use, the likes of **Massachusetts General Hospital, Fox Chase Cancer Centre, John Hopkins, Memorial Sloan Kettering and MD Anderson Cancer Centre** will be on hand to share their focused CTC work in the clinic.



Consultants: Imagine 200+ attendees from the leading drug developers, cancer hospitals and technology providers, all seeking expertise in the areas of regulation, commercialization and reimbursement. World CTC provides unrivalled networking to potential clients in the CTC field.



Technology Solution Providers: World CTC provides you with the platform you need to meet and network with the world's leading drug developers, clinicians and academic institutes, who are investing in the CTC field, all under the same roof at the same time.

"I found this CTC meeting very interesting and made clever, fruitful connections with scientists, clinicians and big pharma companies. Many connections could be made thanks to the speed networking with the exchange of business cards! This meeting was a real success!"

Université Montpellier



Networking at World CTC

Build relationships with industry peers and future clients from across the variety of key stakeholders involved in the CTC field, with over 15+ hours networking time built into the agenda. Take advantage of this time to **break the ice**, **coordinate 1-2-1 meetings** and **exchange contact details**.



Speed Networking

The Speed Networking sessions are a formal part of the conference and a great opportunity to introduce yourself to the attendees that you would like to have more in-depth conversations with later in the conference.

Don't miss these opportunities to get face-to-face time with many of the brightest minds working in the field today and form meaningful business relationships.



Present a Poster

This year's dedicated poster session is open to drug developers, academics and clinicians and is a fantastic platform for you to present your contribution to the CTC field. Meet other attendees and get direct feedback on your work, as well as see how others are pioneering new science.

Posters are not to be used for sales or marketing purposes and all abstracts are subject to approval of Hanson Wade.

Posters can be up to A0 size and need to be submitted to info@hansonwade.com by 26th October 2012.

Don't forget your business cards



Drinks Reception hosted by ON-Q-ITY

After the formal presentations have finished, the networking carries on. The Drinks Reception is an informal part of the conference agenda, allowing you to connect with your peers after the conference in a relaxed atmosphere and continue to forge new relationships with other CTC experts.

Enjoy drinks and canapés at the end of day 1.
Many thanks to our host On-Q-ity

About On-Q-ity

Oncology Quality Clarity

On-Q-ity is an innovative company focused on circulating tumor cell capture and analysis. We are developing unique products and services for clinical researchers and physicians designed to enhance decision-making in disease management across multiple cancer types. Our goals are to accelerate and increase the success of oncology drug development, improve patient treatment outcomes and increase survival rates.



1-2-1 Networking

Use the speed networking to arrange 1-2-1 networking meetings. Get extended face time with leading pharma, biotech, academics and clinicians who are pioneering CTC research.



Bring your Team

To get the most benefit for your organization out of World CTC:

- Split up to cover all of the streams and workshops, then re-group to share experiences
- Bring together multi-departmental project teams from across the globe to exchange knowledge and discuss next steps
- Ensure your organization has a strong presence at the meeting, solidifying your position within the CTC field

“An excellent opportunity to find out what other pharma are doing and what’s emerging. Very valuable”

AstraZeneca

Pre-Conference Workshops

The pre-conference industry workshops offer the opportunity to have your specific challenges within the CTC field tackled by an industry expert in an interactive problem-solving setting. The workshops cover a range of topics including capture, characterization, regulations and commercialization strategies.

- Understand the applications of CTC capture and analytical platforms, and the best practise for commercialization
- Get perspectives from the pharmaceutical sponsor, research collaborator, service provider and regulator on the challenges of implementing CTCs as a routine diagnostic tool
- Uncover the potential of CTCs as a fluid biopsy and their use as a prognostic and companion Dx

“Good speaker selection, very informative & educational”

Genentech

Discounts are available for group bookings

10% discount - 3 delegates

15% discount - 4 delegates

20% discount - 5 or more delegates

To book a group, please email: register@hansonwade.com and you will be assigned a personal contact at Hanson Wade.

Industry Stream

The Industry Stream is designed to provide industry stakeholders with the knowledge to advance the use of CTCs in drug development programs, helping them to optimize clinical trails, negotiate the regulatory landscape and achieve reimbursement.

- Understand how to overcome hurdles to use CTCs as a surrogate end point in clinical trials
- Hear cutting edge technology presentations from the leaders in capture, enumeration and characterization
- Navigate the regulatory pathway to streamline your clinical trials using CTCs, and discover how to achieve maximum reimbursement

Science Stream

The Science Stream explores the exciting developments associated with CTCs and their role in metastatic cancer. This stream looks at the impact of our increasing understanding of cancer biology from molecular characterization of CTCs and how this impacts treatment decisions in the clinic.

- Learn from leading academics about the latest breakthroughs in our understanding of the role of CTCs in metastatic cancer
- Understand how increasing molecular characterization of CTCs is expanding our understanding of the genetic variation in CTC populations and in the primary tumor
- Discuss with leading clinical oncologists how CTCs are being used as a diagnostic, prognostic and a real time monitor to inform treatment choices



Agenda in Full

- Keynote Session
- Networking Session
- Industry Stream
- Science Stream

Day 1

13th November 2012

7.20 Registration, Coffee & Networking

8.20 Chair's Opening Remarks

Plenary Sessions: Circulating Tumor Cells: Capture, Enumeration and Characterization

<p>8.30 Microfluidic Isolation and Molecular Characterization of Circulating Tumor cells</p> <ul style="list-style-type: none"> An introduction to microfluidic approaches to CTC isolation Understanding the molecular pathways implicated in CTC survival Early clinical applications of CTC based genotyping 	<p>Daniel Haber Director Massachusetts General Hospital Cancer Center</p>
<p>9.00 Circulating Tumor Cells (CTC): From Enumeration to Comprehensive Characterization</p> <ul style="list-style-type: none"> Biomarker contribution to development of targeted therapies Use of biomarkers to confirm MOA and predict efficacy Role of CTC-derived biomarkers to direct and monitor therapy 	<p>Nicholas Dracopoli Vice President, Biomarkers Centocor</p>
<p>9.30 Validation of Downstream Mutational Assays Using CTCs From The IsoFlux Rare Cell Access System</p> <ul style="list-style-type: none"> Microfluidic isolation of CTCs with high capture and transfer efficiency Analytical and clinical validation of mutational analysis assay using ultra-sensitive qPCR technology Complimentary genomic, transcriptomic, and proteomic analyses using IsoFlux CTC samples 	<p>Andrea Fan Associate Director of Biology Fluxion Biosciences</p>

10.00 Speed Networking & Morning Refreshments

INDUSTRY STREAM - AM

CTCs as a Tool to Aid Drug Development

- 11.30 **Case Study: Forging Win-Win Relationships to Improve Patient Outcomes: The Novartis Molecular Diagnostics (MDx) Approach to Partnering**
- Explore key drivers for pharma and diagnostic companies to ensure a shared vision can be achieved
 - Identify guiding criteria in partner company selection
 - Provide a case study illustrating NVS MDx's fully integrated Rx-Dx partnering approach
- Yves Dubaquitte**, Director, Business Development & Licensing, **Novartis**

- 12.00 **CellSearch®: Prelude to an Information Rich Future**
- Technology development for rare cell capture and isolation
 - Prognostic applications for drug and diagnostic development
 - Clinical relevance in breast, prostate and colorectal cancer
- Mark Connelly**, Scientific Director, Cellular Research, Janssen Oncology Biomarkers & Site Director, **Veridex**

SCIENCE STREAM - AM

Increasing Our Understanding of Cancer Biology Using CTCs

- 11.30 **The Wide World of Circulating Markers for Cancer Applications**
- A wide variety of marker types from DNA to RNA and from proteins to metabolites are currently being explored as circulating cancer markers
 - The challenge is to compare side-by-side the contribution of marker types to clinically relevant cancer applications
 - A road map from discovery to validation with appropriate technologies and samples is needed to fast track the development of markers
- Samir Hanash**, Program Head, Molecular Diagnostics, **Fred Hutchinson Cancer Research Center**
- 12.00 **CTC Signatures in Breast Cancer Brain Metastasis: Interrogating Mechanisms of Dormancy and Colonization**
- Correlation of CTCs profiling with breast cancer brain metastasis
 - Evaluation of CTCs heterogeneity by complementary CTC technologies and platforms
 - Selection of CTC subsets and identification of candidate biomarkers predictive of breast cancer brain metastasis
 - Interrogation of CTCs metastatic competency in xenografts
 - Understanding the biology of brain-homing CTCs
- Dario Marchetti**, Professor, Departments of Pathology & Immunology and Molecular & Cellular Biology, **Baylor College of Medicine**

12.30 Lunch



Agenda in Full

- Panel Session
- Networking Session
- Industry Stream
- Science Stream

Day 1

13th November 2012

INDUSTRY STREAM - PM

- 1.30 Molecular Characterization of Circulating Tumor Cells: Approaches and Limitations**
- The various molecular strategies that can be utilized to characterize CTCs recovered from blood of cancer patients
 - Common challenges faced when capturing and characterizing CTCs
- Denis Smirnov**, Associate Scientific Director, Oncology Biomarkers, **Janssen Pharmaceuticals**
- 2.00 An Industry Perspective: The Use of CTCs in Clinical Trials of an Antibody-Drug Conjugate for Prostate Cancer**
- Using CTCs and PSA as biomarkers of response to treatment
 - The potential use of CTCs for characterizing tumor expression of antigen
- Bill Olson**, Senior Vice President, R&D, **Progenics**
- 2.30 Considerations in the Development of a Circulating Tumor Cell Technology for Clinical Use**
- Current thinking on the value and promise of evolving CTC technologies
 - Applications of these technologies and their impact on diagnosis, prognosis, response to therapy and in accelerating drug development
- Stanislaw Mikulski**, Senior Medical Director, **EMD Serono**

SCIENCE STREAM - PM

- 1.30 Mathematics of the Fluid Phase of Solid Tumors: Do CTCs Have a Destination?**
- A Markov Chain mathematical model that describes the metastatic pathways
 - Seeding, self-seeding and re-seeding along the timeline of metastatic progression
 - What if the adrenal gland would be a lymphatic destination in lung cancer?
- Peter Kuhn**, Associate Professor, Cell Biology, **The Scripps Research Institute**
- 2.00 3D Nuclear Telomere Parameters Define CTC Subpopulations**
- Introduction to the 3D telomere platform for cancer diagnosis
 - Overview of quantitative software (TeloView and TeloScan)
 - 3D telomeric profiles of CTCs isolated using the ScreenCell device
- Sabine Mai**, Senior Investigator, Manitoba Institute of Cell Biology, Professor, **University of Manitoba**
- 2.30 CTC Interaction With the Extracellular Environment to Promote Metastasis**
- Understanding the biology of the CTC and its interaction with the extracellular environment
 - The therapeutic potential of disrupting this interaction to prevent metastases
- Gavin Robertson**, Director, **Penn State Melanoma Center**

3.00 Afternoon Refreshments & Networking

Plenary Sessions: Circulating Tumor Cells: Capture, Enumeration and Characterization

- 3.30 Oncology Biomarkers and CTC in the Era of Targeted Therapy and Personalized Medicine**
- How to ensure biomarker studies have a comprehensive strategy that addresses the key translational questions and addresses future diagnostic needs to make drugs successful
 - Using biomarkers in oncology to optimize selection of dose and schedule and selection of the right patient subsets
- Vijay Modur**
Head of Diagnostic Discovery
Novartis
- 4.00 Molecular Characterization of CTCs to Bridge the Gap Between Prognosis and Personalized Therapy**
- Realizing the full potential of CTCs in personalized therapy and translational research
 - Techniques that provide a level of purity incompatible with most molecular analyses
 - The DEPArray™ System - using image-based single-cell sorting from small cell loads
- Nicolo Manaresi**
Chief Technology Officer
Silicon Biosystems
- 4.30 Panel Session: Future Applications of CTCs as a Biomarker in Drug Development**
- How CTCs can be used as a surrogate endpoint in clinical trials
 - Current challenges in validating CTCs as a reliable marker
 - Lessons learned from other oncology biomarkers in drug development
- Jaclyn Neely**, Senior Research Investigator, **Bristol Myers Squibb**
Bill Olson, Senior Vice President, R&D, **Progenics**
Steven Pirie-Shepherd, Associate Director, **Pfizer**
Shannon McGrath, Biomarkers and Personalized Medicine, **Eisai**
Chris Chiu, Senior Research Investigator, **Bristol Myers Squibb**

5.00 Chair's Closing Remarks

5.15 Networking Drinks Reception hosted by On-Q-ity 



Agenda in Full

- Keynote Session
- Networking Session
- Industry Stream
- Science Stream

Day 2

14th November 2012

7.20 Registration, Coffee & Networking

8.20 Chair's Opening Remarks

Plenary Session: Furthering the Use of CTCs in Clinical Trials and Patient Management

8.30 Circulating Tumor Cells (CTCs) in Breast Cancer: Enumeration, Molecular Analysis and Targeting of Metastatic Disease

- Enumeration of CTCs demonstrated prognostic significance in metastatic and more recently early breast cancer
- Detection and characterization of CTCs provides a novel tool to identify molecular markers (ER and HER-2) and evaluate the metastatic process (EMT, cancer stem cells)
- Monitoring of CTCs can support the development of more effective personalized therapies in advanced breast cancer

Massimo Cristofanilli
Professor of Medicine
Fox Chase Cancer Center

9.00 Circulating Tumor Cells as Biomarkers: Validation and Qualification in the Context of Unmet Medical Needs

- Disease mechanism of prostate cancer and the role of CTC's in prognosis
- Assessing circulating cells as surrogate drug efficacy markers in the clinic
- Potential for development of new therapies to prostate cancer

Howard Scher
Chief, Genitourinary
Oncology Service
**Memorial Sloan-Kettering
Cancer Center**

9.30 The Role of CTCs as a Companion Diagnostic

- Unbiased identification and profiling of CTCs
- Development of protein and FISH CTC CDx products
- Implementation of CTCs in Pharma clinical trials

David Nelson
President and CEO
Epic Sciences

10.00 A Mini-Device for Rapid Isolation by Size and Extensive Characterization of Rare Circulating Tumor Cells

Yvon Cayre, Chief Scientific Officer
ScreenCell

10.10 Morning Refreshments & Networking

INDUSTRY STREAM - AM

Use of CTCs to Optimize Drug Development Clinical Trials

10.45 New Insights on CTC Biology from Biomarker Analyses from Clinical Trials

- Demonstrating molecular characterization of circulating tumor cells in advance lung cancer clinical trials
 - Investigating the correlation between CTC numbers and clinical response
 - Development of novel CTC biomarkers for the monitoring of patient molecular status in ongoing clinical trials
- Edith Szafer Glusman**, Senior Research Associate, Development Sciences, **Genentech**

11.15 A View from the Strategic Scientific Initiative Centre

- The importance of standardizing CTC procedures for technology deployment in the clinic and drug development
 - An overview of the TCGA program and lessons learned
- Jerry Lee**, Deputy Director, Office of the Director, Center for Strategic Scientific Initiatives, **National Cancer Institute**

11.45 Molecular Characterization of CTCs: Implications for Disease Progression in Preclinical Models and Patients

- The use of single-cell characterization of CTCs using FISH, multiplex PCR and genomic sequencing
 - A comprehensive cross-platform comparison (CellSearch, flow cytometry/FACS, microfiltration, Isoflux)
 - Modeling of CTC biology looking in detail at epithelial-mesenchymal transition
 - Understanding metastasis in preclinical animal studies
- Allison Allen**, Oncology Scientist and Assistant Director, **Western University**

12.15 Lunch

SCIENCE STREAM - AM

Clinical Applications of CTC to Improve Prognosis and Treatment Choices

10.45 Circulating Tumor Cells and Disseminating Tumor Cells as Guides to Drug Selection

- The roles of CTCs and DTCs in the therapeutic management of solid tumors
 - Analytic methods and personalized models for drug testing
- Stefanie Jeffrey**, Chief of Surgical Oncology Research, **Stanford University School of Medicine**

11.15 Circulating Tumor Cells as a Means to Identify Curable Patients with Metastatic Cancer

- CTCs to identify patients most likely to be cured, as well as patients with a propensity for systemic failure
- Using CTCs to match patients with the most appropriate treatment strategy including combinations of local and systemic therapy

Daniel Boffa, Assistant Professor, Section of Thoracic Surgery, **Yale University School of Medicine**

11.45 Circulating Tumor Cells (CTCs) with EMT Phenotype for Predicting Breast Cancer Progression

- The role of Epithelial-Mesenchymal Transition (EMT) in promoting metastasis
- Explaining the loss of EpCAM during EMT
- The clinical association of CTCs with and without EMT property

Sendurai Mani, Assistant Professor, Molecular Pathology, **MD Anderson Cancer Center**



Agenda in Full

- Panel Session
- Networking Session
- Industry Stream
- Science Stream

Day 2

14th November 2012

INDUSTRY STREAM - PM



- 1.15 **CTC-Based Pharmacodynamic Biomarkers in Drug Development and Clinical Trials of Targeted Anti-Cancer Therapeutics**
- Development and validation of assay strategies for assessment of pharmacodynamic biomarkers in CTCs
 - Use of CTC assays in clinical development of targeted anti-cancer therapeutics
- Lihua Wang**, Senior Scientist, Applied Developmental Directorate, **NCI-Frederick, SAIC-Frederick, Frederick National Laboratory for Cancer Research**
- 1.45 **Application of Circulating Tumor Cells to Assessment of Pharmacodynamic Effects of Targeted Agents in Clinical Trials**
- Central problems to be addressed in measuring pharmacodynamic responses in patients
 - Fitness for purpose: Biomarker assay validation
 - The need for SOPs and uniform methods of platform comparison
- Robert Kinders**, Laboratory of Human Toxicology and Pharmacology, Applied/Developmental, Research Directorate, SAIC-Frederick, **NCI-Frederick**
- 2.15 **Circulating Tumor Cells in Ovarian Cancer**
- Application of CTC detection by immunocytochemistry and FISH
 - The use of RT-qPCR for the molecular characterization of CTCs
 - Investigating the clinical impact of CTCs in treatment of ovarian breast cancer
- Robert Zeilinger**, Professor, **Medical University of Vienna**

SCIENCE STREAM - PM

- 1.15 **Epithelial-to-Mesenchymal Transition in Peripheral Blood of Metastatic Breast Cancer Patients without CTCs**
- Evidence for the first time that among all CTCs from peripheral blood of MBC patients you can isolate, independently of the EpCAM enrichment, a cluster of EMT-CTCs
 - Applications of this discovery and the potential impact on patient outcomes
- James Reuben**, Professor, **MD Anderson Cancer Center**
- 1.45 **Isolation of Single, Intact Chromosomes from Single, Selected Ovarian Cancer Cells for *In Situ* Hybridization and Sequencing**
- Updates on progress to develop a technology to isolate patient's single, living cells based upon their cancer-specific, cell surface biomarkers
 - The use of NGS to reveal the molecular profiles of isolated CTCs
- Marek Malecki**, Associate Professor, Director, **Western University of Health Sciences**
- 2.15 **Circulating Tumor Cells as a Prostate Cancer Biomarker and Platform for Personalized Oncology**
- Application of CTC detection by immunocytochemistry and FISH
 - The use of RT-qPCR for the molecular characterization of CTCs
 - Investigating the clinical impact of CTCs in treatment of ovarian breast cancer
- Oscar Goodman**, Medical Director, Clinical Trials Office, **UC San Diego Nevada Cancer Institute**

2.45 **Afternoon Refreshments & Networking**

Plenary Sessions

3.15 Panel Session: Analysis of the Various Technology Platforms Available & How They Perform Cellular Detection, Enumeration & Characterization	Invited Panellists
3.45 Multiparameter Analysis of Potential Circulating Tumor Cells	Jeffrey Chalmers Professor, Department of Chemical and Biomolecular Engineering Ohio State University
4.15 Panel Session: Future Approaches to Exploit the Potential of CTCs in the Clinic	Massimo Cristofanilli Professor of Medicine Fox Chase Cancer Center Howard Scher Chief, Genitourinary Oncology Service Memorial Sloan-Kettering Cancer Center Oscar Goodman Medical Director, Clinical Trials Office UC San Diego Nevada Cancer Institute Daniel Boffa Assistant Professor, Section of Thoracic Surgery Yale University School of Medicine
4.45 Molecular Analysis of Photoacoustically Captured Circulating Tumor Cells	John Viator Associate Professor, Biological Engineering University of Missouri
5.15 Chair's Closing Remarks	
5.30 Poster Session  and One-to-One Networking 	



Agenda in Full

■ Keynote Session
■ Networking Session

Day 3

15th November 2012

7.20 Registration, Coffee & Networking

8.20 Chair's Opening Remarks

8.30 Geometrically Enhanced Differential Immunocapture for Capture and Analysis of Circulating Tumor Cells

- A masterclass detailing method of capture of CTCs with GEDI microdevices
- Implementation of capture techniques in castrate-resistant prostate cancer and other diseases

Brian Kirby
Associate Professor of Mechanical Engineering
Cornell University

Plenary Session: Understanding the Regulatory Environment and Achieving Reimbursement

9.00 Challenges in the Selection and Application of CTC Capture and Analytical Platforms for Use in a Clinical Trial Setting

- The advantages and disadvantages of technical and operational features of platforms in development and commercially available
- Addressing unresolved biologic questions and options for integrating with other circulating and actionable tissue-based tumor molecular biomarker data
- Meeting these challenges through enabling partnerships

John Bloom, President,
Bloom Consulting Services
& Special Government Employee,
FDA

9.30 Personalized Medicine: View From Technology Evaluation Center

- A guide to the frameworks applied for assessing diagnostic tests
- Assessing the value of indirect evidence vs direct evidence
- Evaluating cost-effectiveness and affordability of diagnostic tests

Naomi Aronson
Executive Director, Technology Evaluation Center (TEC),
Blue Cross Blue Shield

10.00 A Stakeholder-Driven Approach to Improving the Evidence Base for Molecular Diagnostics in Cancer

- Understand what types of studies provide adequate evidence for clinical and reimbursement decision making
- How companies and researchers can plan beyond FDA approval

Patricia Deverka
Senior Research Director
Center for Medical Technology Policy (CMTP)/University of North Carolina at Chapel Hill

10.30 Morning Refreshments & Networking

Plenary Session: Advancing Technology in the CTC Field: Increasing Sensitivity and Specificity

11.00 Multispectral Imaging of Circulating Tumor Cells Isolated Using the CTC-Chip

- Advanced techniques for high resolution, multi-parameter image analysis of individual CTCs
- Evaluating the potential of CTCs to be used as a real-time biomarker in the clinic

Shannon Stott
Assistant Professor, Department of Medicine
Harvard Medical School, Massachusetts General Hospital

11.30 Nanobiotechnology for the Capture and Manipulation of Circulating Tumor Cells

- The metastatic adhesion cascade of circulating tumor cells – mimicking leukocyte trafficking
- Rapid isolation of viable CTCs using E-selectin and halloysite nanotubes
- An easy to adopt CTC isolation protocol – published as JoVE video
- Next generation technologies – therapeutic targeting of CTCs to prevent metastasis

Michael King
Associate Professor, Department of Biomedical Engineering
Cornell University

12.00 Recent Progress on Immunomagnetic Isolation of Circulating Tumor Cells in Microchip

- A novel method of microchip-based immunomagnetic CTC detection combining benefits of both immunomagnetic assays and the microfluidic device
- Advances in this method for capture of CTCs and current bottlenecks

John Zhang
Associate Professor, Department of Biomedical Engineering
The University of Texas at Austin

12.30 Lunch

1.30 Advances in Circulating Tumor Cell Analysis: Beyond Enumeration

- CTCs as a non-invasive technique providing material for molecular analysis & gene profiling
- Obtaining information about sensitivity or resistance to new therapeutic targeted agents
- A validation scheme applicable to new CTC enrichment and analysis techniques

Martin Fleisher
Chief, Clinical Chemistry Service, Department of Laboratory Medicine
Memorial Sloan-Kettering Cancer Center



Agenda in Full

Networking Session

Day 3

15th November 2012

2.00 Dielectrophoresis (DEP) in a Microfluidics Platform to Study Isolation and Enrichment of Cancer Cells

- Use of conventional dielectrophoresis in a microfluidic chip to manipulate and isolate HCT116 colorectal cancer cells.
- A detailed report on chip design, flow conditions, dielectrophoretic spectrum of the cancer cells, and the enrichment factor of the colorectal cancer cells from other cells.

Guiren Wang

Assistant Professor, Department of Mechanical Engineering & Biomedical Engineering Program
University of South Carolina

2.30 Novel Nanotechnology Approaches to Circulating Tumor Cell Capture and Characterization

- Introduction to a precision-engineered and novel parylene-microfilter- based, antigen expression-agnostic, open platform that allows capture, enumeration and characterization of CTCs
- The use of nanotechnology to give a longitudinal assessment of CTC as a 'liquid biopsy'
- Practical applications of CTCs as a companion diagnostic and to monitor cancer progression and therapeutic efficacy

Richard Cote

Professor and Chair, Department of Pathology; Director
University of Miami Biomedical Nanoscience Institute, University of Miami Miller School of Medicine

3.00 The Clinical Application of Circulating Tumor DNA

- Dynamics of circulating tumor DNA (ctDNA) in patients with cancer
- An overview of the available technology to detect ctDNA
- Interrogation of ctDNA for early detection and monitoring of minimal residual disease
- The application of ctDNA technology for disease monitoring and detection of therapeutic resistance

Luis Diaz

Associate Professor of Oncology, Director of Translational Medicine
Ludwig Center at Johns Hopkins Kimmel Cancer Center

3.30 Afternoon Refreshments & Networking

4.00 MUC1* is a Stem Cell Growth Factor Receptor that Cancer Cells Hijack to Evade Chemo

- The growth of 75% of cancer cells is mediated by MUC1* discover how this plays a role in metastatic cancer cells
- Understand how MUC1* expression is important in overcoming resistance mechanisms in cancer

Cynthia Bamdad

Chief Scientific Officer
Minerva Biosciences

4.30 Identification and Quantification of Malignant Cells in Cerebrospinal Fluid

- Detecting and quantifying tumor cells in CSF from cancer patients presenting with LM
- A new diagnostic method of leptomeningeal metastases (LM) in Cerebrospinal Fluid (CSF)
- Towards a new gold standard for LM evaluation

Gilbert Faure

Professor of Medicine
Universite de Lorraine

5.00 Strategies for Developing Biomarkers to Target Cancer Stem Cell Agents

- Analysis of CTC technologies for assisting drug development
- Applications for CTC sub-populations and biomarkers
- Integrating and implementing biomarkers into the clinic

Ann Kapoun

Vice President, Translational Medicine,
OncoMed

5.30 Chair's Closing Remarks

"I really enjoyed the wealth of knowledge on CTCs. The networking session was of great benefit. As a person new to CTCs, it was wonderful networking with the other attendees"

Genentech

"Opportunities for individuals interested in CTCs to meet, discuss, and learn the latest technology and progress of CTC's"

Biocept



Interactive Workshops

Have your specific challenges tackled by an industry expert. Workshops provide a very different type of learning environment to normal presentations. Workshops are 3 hour sessions and usually run with 1-2 leaders and consist of about 2-4 short presentations. This allows for in-depth discussion between talks and Q&A, the main aim being to encourage participation from the audience members and allow them to have their specific issues addressed. Workshop attendance is restricted, unlike at the main conference, allowing for a more intimate setting where everyone in the room is interested in the subject matter and the topics can be discussed in greater detail.

Workshop A1: Microfluidic Device Design and Analysis for Capture of Circulating Tumor Cells

Date: 12th November 2012 | Time: 8.30am – 11.30am

Circulating tumor cells have become a more and more central part of cancer research, both fundamental and translational. Because of this, many technological approaches have been implemented to isolate, concentrate, or capture these cells. A subset of these devices have been based on microfluidic technology, meaning that they use microfabrication techniques borrowed from microelectronics to create small geometries that then can be used to perform specific tasks on samples such as blood, urine, or cell aspirates.

Although many microfluidic techniques have been brought to bear in these systems, the relative strengths and weakness are often not apparent from interpretation of biological data and instead come from an engineering analysis of the approaches. To this end, this workshop combines an approachable description of the physics of these different techniques with discussion of their applications.

In this workshop you will learn:

- Physics behind the most common microfluidic cell capture techniques (magnetic beads, immunocoated surfaces, dielectrophoresis, filtration)
- Strengths and weakness of these techniques
- Applications in fundamental and translational research
- Obstacles and opportunities for collaboration and commercial implementation.



Workshop Leader

Brian Kirby
Associate
Professor



Brian Kirby currently directs the Micro/Nanofluidics Laboratory in the Sibley School of Mechanical and Aerospace Engineering at Cornell University. He teaches at Cornell in Ithaca, and is the author of a leading textbook on microscale fluid mechanics. He has received an R&D Top 100 Invention award JD Watson Investigator award, and a Presidential Early Career Award for Scientists and Engineers (PECASE) award, all for work focused on microfluidic devices.

Workshop A2: Emerging Molecular Biomarkers - Blood-Based Strategies to Detect and Monitor Cancer

Date: 12th November 2012 | Time: 8.30am – 11.30am

There is an urgent need for blood-based, noninvasive molecular tests to assist in the detection and diagnosis of cancers in a cost-effective manner at an early stage, when curative interventions are still possible. Blood-based diagnostics can classify tumors into distinct molecular subtypes and monitor disease relapse and response to treatment. Increasingly, biomarker strategies are becoming critical to identify a specific patient subpopulation that is likely to respond to a new therapeutic agent.

This workshop will look at recent advances in all circulating cancer biomarkers comparing side-by-side the contribution of marker types to clinically relevant cancer applications.

Leave this workshop with:

- An understanding of the relevance of CTCs in the cancer clinic to guide therapies
- A clear picture of the landscape of circulating cancer biomarkers and their relevant advantages and disadvantages over each other, including lessons that can be applied from success stories in this field
- A road map from discovery to validation with appropriate technologies and samples needed to fast track the development of markers



Workshop Leader

Samir Hanash
Program Head, Molecular
Diagnostics



Samir is program head for Molecular Diagnostics at the Fred Hutchinson Cancer Research Center. Dr Hanash's interests and expertise focus on the development and application of integrated approaches to the molecular profiling of cancer, with particular emphasis on proteomics. He has been a program principal investigator for several multi-investigator aimed at biomarker discovery and validation using proteomics.



Interactive Workshops

Workshop B: Fluid Biopsy of Solid Tumors: Its Many Uses in Clinical Research and Therapy Management

Date: 12th November 2012 | **Time:** 12.00pm - 3.00pm

Drug targets on CTCs are currently being identified and used as predictive biomarkers for therapeutic stratification of cancer patients. CTC burden is already validated as a prognostic biomarker. Initial data is emerging for the use of the fluid biopsy as a diagnostic tool.

Many uses of rare cell detection in blood as a fluid biopsy are emerging rapidly in oncology. The excitement in the field is driven by innovative technology approaches, and broad clinical and scientific requirements for a tool to study disease evolution in single patients. After technology saturation has been reached, these tools need to demonstrate their performance in specific applications. Each application arena has different requirements.

Leaving this workshop you will understand:


- The use of CTCs as a predictive biomarker to stratify cancer patients in clinical trials
- Applications of the fluid biopsy as companion and prognostic Dx
- How to use rare cells in the blood to achieve broad profiling for risk assessment
- Best practises for use of the fluid biopsy as a tool to aid cancer research



Workshop Leader

Peter Kuhn

Associate Professor,
Cell Biology



Peter has a career long commitment in personalized medicine and individualized cancer patient care. Since 2002 his primary appointment is with Scripps Research, where making cancer a managed disease is the theme of research. His laboratory has developed a reliable way to detect and to characterize CTCs isolated from the blood of cancer patients.

Workshop C: Progress in the Development, Application and Commercialization of CTC Capture and Analytical Platforms for Use in Drug and Diagnostics Development Today

Date: 12th November 2012 | **Time:** 3.30pm - 6.30pm

CTC enumeration and molecular analysis has emerged as among the most promising enabling technologies in cancer drug/molecular diagnostic development and patient care.

This workshop will give you an understanding of:

- The importance of tumor molecular profiling in health care delivery and drug development today.
- The value proposition of CTCs as a noninvasive "liquid biopsy" and business case for translational research investment and diagnostics development strategies.
- Operational and technical advantages and disadvantages of CTC platforms commercially available and in development.
- Integrating data derived from CTCs with those of other circulating tumor markers and tissue-derived molecular profiling.
- Sourcing strategies and enabling partnerships for applying CTC technologies in clinical trials and diagnostics development.

The workshop will frame the above issues and explore solutions to these emerging challenges. Perspectives of the pharmaceutical sponsor, research collaborator, service provider and regulator will be shared through informal facilitated discussion.



Workshop Leader

John Bloom

President & Special
Government Employee


Bloom Consulting Services LLC

Dr Bloom has 29 years of experience in the pharmaceutical industry with leadership roles in preclinical and clinical drug development. He is regarded as an expert in developing phase-appropriate biomarker strategies for drug development, with emphasis on tailoring to individual patients needs, defining technical probability of success and product differentiation. As part of this work he established the Diagnostic and Experimental Medicine Division at Lilly accountable for the above. He is a recognized expert in the development of companion diagnostics in an R&D setting with an extensive track record in partnering.




World CTC at a Glance

Where will the
attendees come from?



Who will be attending?



200+
CTC Experts

15+hrs
of Networking

World's
Largest
CTC
Meeting

*"Excellent snapshot
on the current status
of CTC research,
both in clinic as well
as in the pharma
industry."*


Roche Diagnostics

50+
Speakers


*"Very valuable,
well organized,
good diversity
of speakers."*

Daiichi-Sankyo


How senior are the attendees?



How has World CTC grown?



How will attendees
spend their time?





Sponsorship Opportunities

Leading pharmaceutical and healthcare organizations are crying out for information on what tools exist to aid their drug development. CTC technology platforms that revolutionize capture, enumeration and characterization, alongside a host of new sequencing and genomic technologies, are becoming available to service this need. This is your chance to confirm your place next to the major industry players.

Are you looking to capitalize on this boom and get huge exposure for your company in front of the key decision makers actively looking for CTC solutions?

Why Sponsor?

Hanson Wade's **World CTC** meeting is like no other. It is the CTC meeting of the year. Over the last three years it has continued to expand. With more and more eyes fixed on the CTC space, all the leading players are choosing to attend **World CTC**. It is the perfect platform to access key decision makers and influencers in the commercial sector.

Who should sponsor?

Platform Providers: CTC Capture, Enumeration, Molecular Characterization, Imaging and Analysis

Scientific Service Providers: CROs, Diagnostic Testing Specialists, Reference Labs

Industry: Innovative Biotechs, Regulatory Specialists, Reimbursement Consultants, Commercialization Advisors, Venture Capitalists

"The World CTC Summit attracts important members across the CTC study community including diagnosticians, drug developers, technology providers and clinicians"

Silicon Biosystems

Align your company with a high potential market

Influence the direction of industry thinking

Build credible relationships with future buyers

What options are available?

Scientific Presentation: Demonstrate thought leadership and present your message through a scientific presentation built into the agenda.

Private Lunch: Hosting a lunch with a pre-selected group of attendees is an excellent way to interact and impress prospective clients. This hugely personal networking opportunity gives you one-to-one access with a hand-picked audience selected by you.

Exhibition Booth: The best opportunity to showcase your company's products, services and technology. All booths are in a central location, surrounded by all the networking functions and are ideally placed to allow you to interact with the attendees searching for solutions.

Innovation Panel: Ideal for up-and-coming companies who are looking to showcase their innovations. This is an excellent way to drive customers to your meeting area where relationships can be further forged or strengthened.

Bespoke sponsorship packages are available – we would be happy to discuss your specific requirements.



For information on sponsorship, please contact Miles Harley at:
mharley@hansonwade.com
or call +44 (0) 20 3141 8797



Sponsors



Epic Sciences, Inc. provides customized assay development services to aid biotechnology and pharmaceutical companies in clinical trials and drug discovery. The company also offers a liquid biopsy which has broad applicability for both the enumeration and molecular characterization of CTCs which will facilitate cancer management through earlier diagnosis, staging, and therapeutic selection. Epic Sciences was incorporated in 2008 and is based in San Diego, California. www.epicsciences.com



Fluxion Biosciences, Inc. has developed the IsoFlux System for isolating circulating tumor cells with high recovery, purity, viability, and transfer efficiency to downstream analyses.

Fluxion's proprietary microfluidic approach delivers highly uniform and concentrated magnetic fields that enable more efficient recovery of target cells coupled to immunomagnetic particles. The benchtop instrument outputs target cells ready for use in PCR, FISH, sequencing, and microscopy-based assays.

The IsoFlux System has been adopted by big pharma, biotech, diagnostic developers, and clinical researchers across the world to pursue their circulating tumor cell, biomarker discovery, and oncology diagnostics programs.

Fluxion is a global provider of cellular analysis instrumentation for the research, drug discovery, and diagnostics industry. Its products are used by the world's leading pharmaceutical, biotechnology, and research institutions. www.fluxionbio.com



ScreenCell was set-up with the belief that just enumerating CTC without easily characterizing them, was not enough to allow the early detection of disease, the discovery of biomarkers to predict treatment responses and potentially follow-up the disease progression.

ScreenCell devices were designed compatible with existing *In Vitro* Diagnostics (IVD) assays and platforms, enabling the effective isolation of fixed or healthy live tumor cells, thus allowing enumeration, cytomorphology evaluation as well as cell culture and molecular biology. www.screencell.com



Silicon Biosystems is a leading medical device manufacturer in the detection and recovery of single cells for cancer research and prenatal testing. The company's DEPAArray™ platform can isolate and collect 100% pure populations of rare cells, such as circulating tumor cells, because of its unique ability to image and recover individual cells. The DEPAArray™ platform makes it possible to find, sort, select and separate individual or groups of cells for molecular analysis or culturing. www.siliconbiosystems.com



Veridex, LLC, a Johnson & Johnson company, is an organization dedicated to providing physicians with high-value diagnostic oncology products. Veridex's IVD products may significantly benefit patients by helping physicians make more informed decisions that enable better patient care. Veridex's Clinical Research Solutions provide tools and services that may be used for the selection, identification and enumeration of targeted rare cells in peripheral blood for the identification of biomarkers, aiding scientists in their search for new, targeted therapies. For more information, visit www.veridex.com and www.veridex-crs.com



Academic and Clinician Attendees at World CTC

The CTC field is dependent on the cutting edge research coming out of the leading academic institutions to help fuel innovation in the pharma industry. Alongside this work, cancer hospitals are leading the way in implementing groundbreaking research in the clinical setting, to impact patient diagnosis, prognosis and treatment regimes.

This year you will be able to attend a dedicated Science Stream designed to focus on the advances in our understanding of metastatic cancer as a disease and the role of CTCs in this process. The Science Stream will provide the latest clinical data from clinicians who are working day-to-day with CTCs in leading cancer hospitals across the country.



Highlights not to miss at World CTC:

Microfluidic Isolation and Molecular Characterization of Circulating Tumor cells



Daniel Haber
Director



Circulating Tumor Cells (CTCs) in Breast Cancer: Enumeration, Molecular Analysis and Targeting of Metastatic Disease



Massimo Cristofanilli
Professor of Medicine



Circulating Tumor Cells as Biomarkers: Validation and Qualification in the Context of Unmet Medical Needs



Howard Scher
Chief, Genitourinary Oncology Service



Why should you join World CTC?

- 1 Get clinical updates from the leading clinical oncologists on how CTCs are being increasingly used as a diagnostic, prognostic and real time monitor of treatment success
- 2 Learn how advances in molecular characterization of CTCs is increasing our understanding of the genetic variation found in CTC populations, and how this relates to the primary tumor
- 3 Understand the role that CTCs play in the progression of metastatic cancer and how this can help open up new therapeutic avenues
- 4 Hear how innovative biotechs and pharma are utilizing CTCs in clinical trials
- 5 Present your work to the CTC community in a poster and get feedback from the industry
- 6 Network with every leading player (large and small) in the CTC space and identify new collaboration opportunities
- 7 Understand how the hottest spinouts are commercializing new capture, enumeration, and characterization platform technologies

To facilitate attendance from Academics, we are pleased to offer a discounted rate of **\$1349**

Patient Care Givers are invited to attend the meeting at a discounted rate of **\$699**



Present your work at World CTC

This is your chance to not just hear the science but to join the debate as well. This year we'll be holding a dedicated poster session to highlight the most interesting projects under development. **Open to drug developers, academics and clinicians** this is an unparalleled opportunity to present your contribution to the field. Get direct feedback on your lab's work and see how others are pioneering new science.

Posters are not to be used for sales or marketing and all abstracts are subject to approval by the conference organizers.

Posters can be up to A0 size and need to be submitted to info@hansonwade.com before 26th October 2012



Speakers in Full

Leading Clinicians



Daniel Boffa

Assistant Professor, Section of Thoracic Surgery



Yale School of Medicine

Dan is a Thoracic Surgeon at Yale University School of Medicine, specializing in minimally invasive approaches to lung and esophageal cancer. His research interests are in dissemination of cancer, and the ability to cure patients with limited spread.

Talk Title: Circulating Tumor Cells as a Means to Identify Curable Patients with Metastatic Cancer **Date:** 14th November



Massimo Cristofanilli

Professor of Medicine



Massimo's major research interest is the detection, characterization and possible therapeutic targeting of occult (microscopic) disease in breast cancer. Massimo's most recent studies focus on the biological characterization of CTCs and the link with cancer stem cells.

Talk Title: Circulating Tumor Cells (CTCs) in Breast Cancer: Enumeration, Molecular Analysis and Targeting of Metastatic Disease **Date:** 14th November



Luis Diaz

Associate Professor of Oncology, Director of Translational Medicine



Luis is associate professor of oncology at John Hopkins Cancer Centre and has published extensively on the use of circulating DNA as a cancer biomarker

Talk Title: The Clinical Application of Circulating Tumor DNA **Date:** 15th November



Martin Fleisher

Chief, Clinical Chemistry Service, Department of Laboratory Medicine



Martin is an expert in the discovery and use of markers for detecting and monitoring cancer. His current research focuses on biomarker assay development and validation of CTC analyses for clinical management and use in drug development.

Talk Title: Advances in Circulating Tumor Cell Analysis: Beyond Enumeration **Date:** 15th November



Oscar Goodman

Medical Director, Clinical Trials Office



Oscar is the Medical Director of the Clinical Trials Office at the UC San Diego Nevada Cancer Institute. His talk focuses on CTCs as a prognostic biomarker for prostate cancer.

Talk Title: Circulating Tumor Cells as a Prostate Cancer Biomarker and Platform for Personalized Oncology **Date:** 14th November



Daniel Haber

Director



Daniel's laboratory has recently established the application of a novel microfluidic technology for quantifying and purifying circulating tumor cells from the blood of patients with various epithelial cancers.

Talk Title: Microfluidic Isolation and Molecular Characterization of Circulating Tumor cells **Date:** 13th November



Stefanie Jeffrey

Chief of Surgical Oncology Research



Stephanie's laboratory studies tumor cells involved in the metastatic spread of cancer with the aim of improving methods for selecting patient-specific therapies through technology development and patient-derived models for drug sensitivity testing.

Talk Title: Circulating Tumor Cells and Disseminating Tumor Cells for Guiding Cancer Therapy **Date:** 14th November



Gavin Robertson

Director



Gavin leads the melanoma effort at Penn State. He runs a well-funded research program involving identification and validation of novel therapeutic targets, discovery & development of new treatments and clinical evaluation of these experimental drugs in patients.

Talk Title: CTC Interaction With the Extracellular Environment to Promote Metastasis **Date:** 13th November



Howard Scher

Chief, Genitourinary Oncology Service



Howard is the Principal Investigator of the Prostate Cancer Clinical Trials Consortium (PCCTC), a 13-center research collaborative, funded by the Department of Defense and the Prostate Cancer Foundation, and headquartered at MSKCC.

Talk Title: Circulating Tumor Cells as Biomarkers: Validation and Qualification in the Context of Unmet Medical Needs **Date:** 14th November



Shannon Stott

Assistant Professor, Department of Medicine



Shannon Stott is an Assistant Professor at Harvard Medical School. Her expertise in microfluidic device design has been applied to CTCs for the past five years, and she is a co-inventor of the Herringbone CTC-Chip.

Talk Title: Multispectral Imaging of Circulating Tumor Cells Isolated Using the CTC-Chip **Date:** 15th November

Media Partners

ASDReports

market research, analysis & forecast

Libertas Academica

Freedom to Research

Journal of Cancer Research Updates

espicom

RESOURCES IN INTELLIGENCE

Lifescience Global

pharmaphorum

bringing healthcare together

PharmaVOICE

Technology Networks.com

Current Drug Targets

Evening Drinks Speaker



Michael Stocum

President & CEO



Michael Stocum joined On-Q-ity as President and CEO in February of 2012. He is also President and Founder of Personalized Medicine Partners. In his 20 year career, Michael has developed or commercialized multiple novel molecular diagnostic products.

Talk Title: Drinks Reception Address **Date:** 13th November

"An eye opening experience. As I am in the process of evaluating CTC technology for my company, the event was invaluable"

MolecularMD



Speakers in Full

Pioneering Drug Developers and Technology Providers



Cynthia Bamdad
Chief Scientific Officer



Cynthia is the CEO & CSO of Minerva Biotechnologies and is a recognised leader in the field of nanotechnology, having invented the first method to form biochip surfaces on nanoparticles and to use those in testing and drug discovery.

Talk Title: MUC1* is a Stem Cell Growth Factor Receptor that Cancer Cells Hijack to Evade Chemo
Date: 15th November



Yvon Cayre
Chief Scientific Officer



Yvon is currently a tenured professor of medicine at the Robert Debré Hospital in Paris and also acts as CSO of the ScreenCell R&D where he created a new device for isolating and analyzing circulating tumour cells from patients.

Talk Title: A Mini-Device for Rapid Isolation by Size and Extensive Characterization of Rare Circulating Tumor Cells
Date: 14th November



Chris Chiu
Senior Research Investigator



Chris is currently Senior Research Investigator at BMS and has a wealth of experience in the area of cancer biomarkers in drug development.

Talk Title: Future Applications of CTCs as a Biomarker in Drug Development
Date: 13th November



Mark Connelly
Scientific Director, Cellular Research, Janssen Oncology Biomarkers & Site Director



Mark is Director of Cellular Research and Site Director for Veridex's Huntingdon Valley Location. He previously served as Vice President of Reagent Development for Immunicon Corp.

Talk Title: CellSearch®: Prelude to an Information Rich Future
Date: 13th November



Nicholas Dracopoli
Vice President, Biomarkers



Nicholas is Vice President/Head of Oncology Biomarkers at Janssen R&D, LLC of Johnson & Johnson. In this role he is responsible for biomarker discovery, development and application for oncology products.

Talk Title: Circulating Tumor Cells (CTC): From Enumeration to Comprehensive Characterization
Date: 13th November



Yves Dubaquier
Director, Business Development & Licensing



Yves joined Novartis in August 2009. In his current role of Director, Business Development & Licensing, he is engaged in the full spectrum of MDx partnering activities including in-licensing, out-licensing and M&A projects.

Talk Title: Case Study: Forging Win-win Relationships to Improve Patient Outcomes: The Novartis Molecular Diagnostics (MDx) Approach to Partnering
Date: 13th November



Andrea Fan
Associate Director of Biology



Andrea has over 15 years of experience in therapeutic and diagnostic product development in oncology and immunology at ChemoCentryx, Affymax-GSK, diaDexus, and Maxygen. She holds a Ph.D. in Immunology from University of Virginia.

Talk Title: Validation of downstream mutational assays using CTCs from the IsoFlux Rare Cell Access System
Date: 13th November



Edith Szafer Glusman
Senior Research Associate, Development Sciences



Edith is a Senior Research Associate in Oncology Biomarker Development, Genentech. She received her PhD in Biochemistry at Israel Institute of Technology, and a Cell Biology Postdoctoral Fellow at the Stanford School of Medicine.

Talk Title: New Insights on CTC Biology from Biomarker Analyses from Clinical Trials
Date: 14th November



Ann Kapoun
Vice President, Translational Medicine



Ann is VP of Translational Medicine at OncoMed Pharmaceuticals Inc. Redwood City, CA where she is responsible for developing clinical biomarker strategies and assays to demonstrate proof of principle in oncology trials.

Talk Title: Strategies for Developing Biomarkers to Target Cancer Stem Cell Agents
Date: 15th November



Nicolo Manaresi
Chief Technology Officer



Prior to co-founding Silicon Biosystems, Nicolo was a research fellow at the University of Bologna and a long-time consultant to STMicroelectronics. He holds a Degree and Ph.D. from the University of Bologna.

Talk Title: Molecular Characterization of CTCs to Bridge the Gap Between Prognosis and Personalized Therapy
Date: 13th November



Shannon McGrath
Biomarker and Personalized Medicine



Shannon has extensive experience working at Eisai with biomarkers to achieve the goal of personalised medicine in oncology.

Talk Title: Panel Session: Future Applications of CTCs as a Biomarker in Drug Development
Date: 13th November



Vijay Modur
Head of Diagnostic Discovery



Vijay is currently head of diagnostic discovery at Novartis. He has particular interest in novel and innovative clinical development, including biomarker-based personalized medicine and innovative approaches to study design and development.

Talk Title: Oncology Biomarkers and CTC in the Era of Targeted Therapy and Personalized Medicine
Date: 13th November



Stanislaw Mikulski
Senior Medical Director



Stanislaw is currently senior medical director at EMD Serono and has extensive experience in the use of biomarkers as diagnostics to aid personalised medicine in oncology.

Talk Title: Considerations in the Development of a Circulating Tumor Cell Technology for Clinical Use
Date: 13th November



Jaclyn Neely
Senior Research Investigator



Cancer researcher and geneticist with particular expertise in synergistically applying state-of-the-art genomic, proteomic and cellular technologies in the discovery and clinical implementation of novel oncology biomarkers.

Talk Title: Panel Session: Future Applications of CTCs as a Biomarker in Drug Development
Date: 13th November



David Nelson
President and Chief Scientific Officer



David has been involved in the creation and/or advancement of many start-up companies and has served as a grant reviewer for the NCI Director's Challenge Grant.

Talk Title: The Role of CTCs as a Companion Diagnostic
Date: 14th November



Speakers in Full



Bill Olson
Senior Vice President, R&D



Bill joined Progenics in 1994. He has also served as a Research Scientist at Johnson & Johnson, and as a Development Scientist at MicroGeneSys. He received his PhD from MIT.

Talk Title: Panel Session: Future Applications of CTCs as a Biomarker in Drug Development
Date: 13th November



Steven Pirie-Shepherd
Associate Director



Steven has ten years of drug discovery and development experience with various San Diego biotech. He's currently exploring biomarkers as a means of guiding the development of anticancer therapies at Pfizer.

Talk Title: Can Circulating Tumor Cells Play a Role in Guiding ADC Drug Development and Therapy?
Date: 13th November



Denis Smirnov
Associate Scientific Director,
Oncology Biomarkers



Denis has worked in various industrial and academic settings, including Immunicon Corp, Howard Hughes Medical Institute and On-Q-ity. Denis currently is an Associate Scientific Director at Janssen Pharmaceuticals.

Talk Title: Molecular Characterization of Circulating Tumor Cells: Approaches and Limitations
Date: 13th November

Leading Academics



Alison Allan
Oncology Scientist and Assistant Director



Alison holds an HBSc in Molecular Biology and a PhD in Biomedical Sciences. Her research is focused on mechanisms of metastasis, in particular the study of CTCs and CSCs in animal models and patients.

Talk Title: Molecular Characterization of CTCs: Implications for Disease Progression in Pre-clinical Models and Patients
Date: 14th November



Jeffrey Chalmers
Professor, Department of Chemical and Biomolecular Engineering



Jeff is a Professor in the Department of Chemical and Biomolecular at The Ohio State University. He is also Director of the Analytical Cytometry and Cell Sorting Shared Resource (ACCSSR) at the Ohio State University Medical School.

Talk Title: Multiparameter Analysis of Potential Circulating Tumor Cells
Date: 14th November



Richard Cote
Professor and Chair, Department of Pathology; Director



Richard has recently developed nanoscale technologies for cancer diagnostic applications, including bionanosensors for the detection of serum tumor markers, and technologies for the capture and characterization of circulating tumor cells.

Talk Title: Novel Nanotechnology Approaches to Circulating Tumor Cell Capture and Characterization
Date: 15th November



Samir Hanash
Program Head, Molecular Diagnostics



Samir's interests and expertise focus on the development and application of integrated approaches to the molecular profiling of cancer. He has been a program principal investigator for several multi-investigator aimed at biomarker discovery and validation using proteomics.

Talk Title: The Wide World of Circulating Markers for Cancer Applications
Date: 13th November



Gilbert Faure
Professor of Medicine



Gilbert is a Professor of Immunology at the University of Lorraine and a qualified clinician. Gilbert's work focuses on rare cell events and innovative cellular biomarkers in oncology and cardiovascular disorders.

Talk Title: Identification and Quantification of Malignant Cells in Cerebrospinal Fluid
Date: 15th November



Robert Kinders
Laboratory of Human Toxicology and Pharmacology, Applied/Developmental, Research Directorate, SAIC-Frederick



Robert's laboratory develops and validates assays to measure the effects of new, targeted anticancer agents in first-in-man clinical trials. He is actively engaged in CTC applications development for support of NCI sponsored clinical trials.

Talk Title: Application of Circulating Tumor Cells to Assessment of Pharmacodynamic Effects of Targeted Agents in Clinical Trials
Date: 14th November



Michael King
Associate Professor, Department of Biomedical Engineering



Michael King is an associate professor of biomedical engineering at Cornell University. He is an expert on circulating tumor cell adhesion, and the recipient of awards from the NSF, ASME, and AACC.

Talk Title: Nanobiotechnology for the Capture and Manipulation of Circulating Tumor Cells
Date: 15th November



Brian Kirby
Associate Professor of Mechanical Engineering



Brian currently directs the Micro/Nanofluidics Laboratory in the Sibley School of Mechanical and Aerospace Engineering at Cornell University, following several years at Sandia National Laboratories in Livermore, California.

Talk Title: Geometrically Enhanced Differential Immunocapture for Capture and Analysis of Circulating Tumor Cells
Date: 15th November



Peter Kuhn
Associate Professor, Cell Biology



Peter has a career long commitment in personalized medicine and individualized cancer patient care. His laboratory has developed a reliable way to detect and to characterize CTCs isolated from the blood of cancer patients.

Talk Title: Mathematics of the Fluid Phase of Solid Tumors: Do CTCs Have a Destination?
Date: 13th November



Jerry Lee
Deputy Director, Office of the Director, Center for Strategic Scientific Initiatives



Jerry serves as Health Sciences Director within the National Cancer Institute's Office of the Director where he has dual roles as Deputy Director for both the Center for Strategic Scientific Initiatives and the Center for Cancer Genomics.

Talk Title: A View from the Strategic Scientific Initiative Centre
Date: 14th November



Sabine Mai
Senior Investigator, Manitoba Institute of Cell Biology, Professor



Sabine did her post-doctoral training at the Basel Institute for Immunology. Her research training included collaborative studies at NIH/NCI.

Talk Title: 3D Nuclear Telomere Parameters Define CTC Subpopulations
Date: 13th November



Marek Malecki
Associate Professor, Director



Marek's major expertise is in molecular profiling of cancer cells. Cancer suicide therapy, which he developed, was honored as one of most promising future developments in medicine.

Talk Title: Isolation of Single, Intact Chromosomes from Single, Selected Ovarian Cancer Cells for in situ Hybridization and Sequencing
Date: 14th November



Speakers in Full



Sendurai Mani

Assistant Professor, Molecular Pathology



Sendurai is assistant professor of molecular pathology at MD Anderson Cancer Center. His lab is primarily interested in understanding the biology of cancer progression.

Talk Title: Circulating Tumor Cells (CTCs) with EMT Phenotype for Predicting Breast Cancer Progression
Date: 14th November



Dario Marchetti

Professor, Departments of Pathology & Immunology and Molecular & Cellular Biology



Dario has made seminal contributions elucidating mechanisms of brain metastasis, and pioneered understandings of CTC biology by conceptualizing, developing, and directing the CTC Core.

Talk Title: CTC Signatures in Breast Cancer Brain Metastasis: Interrogating Mechanisms of Dormancy and Colonization
Date: 13th November



James Reuben
Professor



James received his doctorate in tumor immunology from India. At present, he is working on magnetic separation of CTCs, and developing protocols for reliable identification and enumeration.

Talk Title: Epithelial-to-Mesenchymal Transition in Peripheral Blood of Metastatic Breast Cancer Patients without CTCs
Date: 14th November



John Viator

Associate Professor, Biological Engineering



John Viator is an associate professor in the Biological Engineering Department at the University of Missouri. He also holds an adjunct appointment in the Department of Dermatology.

Talk Title: Molecular Analysis of Photoacoustically Captured Circulating Tumor Cells
Date: 14th November



Guiren Wang

Assistant Professor, Department of Mechanical Engineering & Biomedical Engineering Program



Guiren's research and interests include micro/nanofluidics sensor, lab-on-a-chip, biomechanics, drug delivery, fluid mechanics, turbulence and mixing, optical measurement, fluorescence, bioreactor and tissue engineering.

Talk Title: Dielectrophoresis (DEP) in a Microfluidics Platform to Study Isolation and Enrichment of Cancer Cell
Date: 15th November



Lihua Wang

Senior Scientist, Applied Developmental Directorate



Lihua's research is currently focusing on pharmacodynamics of targeted anti-cancer therapeutics by using circulating tumor cells (CTCs)-based strategies for assessment of drug-induced mechanistic biomarkers.

Talk Title: CTC-Based Pharmacodynamic Biomarkers in Drug Development and Clinical Trials of Targeted Anti-Cancer Therapeutics
Date: 14th November



Robert Zeilinger
Professor



Robert Zeilinger has a background in biochemistry and zoology at the University of Vienna. He is Director of the Molecular Oncology Group at the Department of Obstetrics and Gynecology at the Medical University of Vienna.

Talk Title: Circulating Tumor Cells in Ovarian Cancer
Date: 14th November



John Zhang

Associate Professor, Department of Biomedical Engineering



John's research focuses on exploring bio-inspired miniaturization technology and scale-dependent physical phenomena to develop new diagnostic devices and methods on probing complex cellular processes critical to disease development such as cancer.

Talk Title: Recent Progress on Immunomagnetic Isolation of Circulating Tumor Cells in Microchip
Date: 15th November

Regulation and Reimbursement Specialists



Naomi Aronson

Executive Director, Technology Evaluation Center (TEC)



Naomi is Executive Director of the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). She has overseen TEC's development as a nationally recognized technology assessment program.

Talk Title: Personalized Medicine: View From Technology Evaluation Center
Date: 15th November



John Bloom

President & Special Government Employee

Bloom Consulting Services LLC

Jack is regarded as expert in developing phase-appropriate biomarker strategies for drug development, with emphasis on tailoring to individual patients needs, defining technical probability of success and product differentiation.

Talk Title: Challenges in the Selection and Application of CTC Capture and Analytical Platforms for Use in a Clinical Trial Setting
Date: 15th November



Patricia Deverka

Senior Research Director



Patricia's research responsibilities reflect her broad expertise in comparative effectiveness research and genomics and personalized medicine, including for example CANCERGEN, molecular diagnostics EGD and the CER Institute.

Talk Title: A Stakeholder-Driven Approach to Improving the Evidence Base for Molecular Diagnostics in Cancer
Date: 15th November

Onsite at World CTC





Venue & Accommodation

Hyatt Regency Boston
One Avenue de Lafayette
Boston MA 02111
United States

World CTC Venue:



<http://regencyboston.hyatt.com>

Booking Accommodation:

To book your accommodation at the Hyatt Regency Boston, please follow the link below:

<https://resweb.passkey.com/go/HansonWade>

Rate: \$280 +tax (Standard room)
Tel: +1 617 912-1234
Subject to availability.

Location and Directions from the Airport:

From Logan Airport (BOS)

Driving directions: 4.4 miles from Hyatt Regency Boston, follow directions for Ted Williams Tunnel. Go through tunnel and follow signs for exit 25, S. Station. At top of ramp, take a right onto Congress St, follow to "D" St, take a right onto "D" St, and your 2nd right onto Summer St. Follow Summer St to Kingston St, turn left into Kingston St then right into Bedford St. Take next left onto Chauncy St then right onto Ave De Lafayette. Hyatt Regency Boston is on your right.

Estimated taxi fare: \$25

Parking On-Site:

Onsite parking is available. \$43 per day.

Registration & Pricing

Priority Code:

MKT

Register

Online: www.ctc-summit.com
Tel: +1 212 537 5898
Fax: +1 212 537 5898
Email: register@hansonwade.com

Mail:
Hanson Wade
304 Park Avenue South
11th Floor
New York, NY 10010

Team discounts

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

*All discount offers (including team discounts) require payment at the time of registration to receive any discount. 'Early Bird' discounts require payment at time of registration and on or before the cut-off date to receive any discount. All discount offers cannot be combined with any other offer. The conference fee includes lunch, refreshments and course documentation. The fee does not include travel or hotel accommodation.

Event prices

Package	Register and Pay before Friday 27th July*	Register and Pay before Friday 24th August*	Register and Pay before Friday 28th September*	Standard Pricing
<input type="radio"/> 3 day conference +3 workshops	\$3946 (SAVE \$550)	\$3996 (SAVE \$500)	\$4096 (SAVE \$400)	\$4196 (SAVE \$300)
<input type="radio"/> 3 day conference +2 workshops	\$3447 (SAVE \$450)	\$3497 (SAVE \$400)	\$3597 (SAVE \$300)	\$3897
<input type="radio"/> 3 day conference +1 workshop	\$2948 (SAVE \$350)	\$2998 (SAVE \$300)	\$3098 (SAVE \$200)	\$3298
<input type="radio"/> 3 day conference only	\$2449 (SAVE \$250)	\$2499 (SAVE \$200)	\$2599 (SAVE \$100)	\$2699
<input type="radio"/> Half day workshop (each)	\$599			

	NOT FOR PROFIT ORGANIZATIONS	PATIENT CAREGIVERS
<input type="radio"/> 3 day conference + 3 workshops	\$2246	\$1296
<input type="radio"/> 3 day conference + 2 workshops	\$1947	\$1097
<input type="radio"/> 3 day conference + 1 workshop	\$1648	\$898
<input type="radio"/> 3 day conference only	\$1349	\$699
<input type="radio"/> Half day workshop (each)	\$299	\$199

Please select your choice of workshop: Workshop A1 ☐ OR Workshop A2 ☐ Workshop B ☐ Workshop C ☐

Delegate details

Title:Forename:Surname:

Job Title:Company/Organization:

Email:Direct Manager:

Address:Postcode:

Country:Direct Telephone:

Direct Fax:Mobile:

Switchboard:Signature:Date:

Payment details

Number of delegates:Amount: \$Conference Documentation:Credit Card:VisaMastercardAmex

Card No:Valid from:Expiry Date:

Cardholders name:

Signature:Date:

Card billing address:

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Charter House, 13-15 Carteret Street, London SW1H 9DJ